Tag Archives: IPO

Biotech IPO Window – Still Ajar?

IPO plans for Quark Pharmaceuticals were officially put on hold last week as markets continue to drop and investors shy away from risk. This is the fifth IPO withdrawal since June. Ambit, Agendia and Clarus cited market reasons for their withdrawals, and Advanced BioHealing sought a higher valuation exit via acquisition. Only one biotech IPO, Horizon Pharma, has made it out in the last six months. Of the nine biotech IPOs so far in 2011, Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , ,

Biotech IPO Update for May 18th, 2011

There are now eight biotech IPOs for 2011, bringing the total for the recent US IPO window to 28. Post-IPO performance is finally picking up with the median return at +14% for these 28 IPOs. Advanced BioHealing was scheduled to IPO this week, but Shire (SHGPY) came in with a $750M offer to buy the company. Sagent Pharmaceuticals (SGNT) was the most recent IPO, back in April. Sagent is a specialty pharma company selling injectable Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

IPO Update – April 5th, 2011

The six biotech IPOs of 2011 have followed 2010′s IPO trends; all took significant haircuts getting out the door and most are performing modestly.  The median downward adjustment in the amount raised for 2011′s biotech IPOs stands at -31%, the average is at -33%.  These companies have raised a median and mean amount of $49M and $54M, respectively. Despite the lukewarm IPO reception biotech stocks have faced in the U.S., two more U.S. companies have filed to go public since the close of 2010.  Specialty pharmaceutical Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , ,

IPO UPDATE – JANUARY 4th, 2011

In 2010 we saw the return of the Biotech IPO. In the US, 17 biotech companies went public, up from 3 in 2009, and only 1 in 2008. However, almost all of them had to accept a lower price than was sought in the initial filing. The average downward adjustment to the amount raised was 25%. The median and mean amount raised in the US in 2010 was $53M and $84M, respectively. Since the IPO Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , ,

IPO Update – November 11th, 2010

Today’s IPO from Complete Genomics (GNOM) brings the US biotech IPO list to 17 since the latest window opened up back in August 2009. The Complete Genomics IPO makes it two in a row for DNA sequencing companies hitting the Nasdaq, with Pacific Biosciences (PACB) debuting just 10 trading days ago. Once again, however, we see the IPO price come in below the expected price: Complete Genomics priced its initial public offering of stock at Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , ,